Get the Stockscreener App
5.53
0.18%
0.03
Monte Rosa Therapeutics Inc stock is traded at $5.53, with a volume of 281.80K.
It is up +0.18% in the last 24 hours and down -15.36% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$5.50
Open:
$5.49
24h Volume:
281.80K
Relative Volume:
0.33
Market Cap:
$331.14M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.4688
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
-5.65%
1M Performance:
-15.36%
6M Performance:
-5.33%
1Y Performance:
-12.54%
1-Day Range:
$5.37
$5.66
1-Week Range:
$5.25
$6.26
52-Week Range:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
5.50 | 331.14M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.01 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.63 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.11 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.75 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Monte Rosa's Molecular Glue Technology Transform Drug Development? CEO Presents Latest Advances - StockTitan
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN (NASDAQ:GLUE) - Seeking Alpha
Janney Montgomery Scott LLC Acquires Shares of 13,315 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
SG Americas Securities LLC Has $116,000 Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The Potential Rise in the Price of Monte Rosa Therapeutics Inc (GLUE) following insiders activity - Knox Daily
BlackRock, Inc. Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 8.8% in January - MarketBeat
JPMorgan Chase & Co. Has $98,000 Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vanguard Group Inc. Expands Stake in Monte Rosa Therapeutics Inc. - GuruFocus.com
Barclays PLC Acquires 43,499 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - Defense World
Jane Street Group LLC Sells 51,005 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Yahoo Finance
(GLUE) Technical Data - Stock Traders Daily
Monte Rosa outlines 2025 clinical milestones - Investing.com India
Monte Rosa outlines 2025 clinical milestones By Investing.com - Investing.com Australia
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength - TipRanks
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - The Manila Times
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Barclays PLC - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Purchases 197,247 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
State Street Corp Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com
Monte Rosa Therapeutics appoints new board member - Investing.com
Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK
Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan
Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria
Monte Rosa reports promising cancer therapy results - Investing.com
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times
Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire
Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech - Fierce Biotech
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):